LXH254 is primarily used in research settings as a potent and selective inhibitor of the ERK1/2 signaling pathway, which plays a key role in cell proliferation and survival. It is investigated for its potential in treating cancers driven by mutations in the RAS/RAF/MEK/ERK pathway, such as melanoma, non-small cell lung cancer, and colorectal cancer. Due to its ability to suppress tumor growth and overcome resistance to upstream inhibitors like BRAF or MEK inhibitors, LXH254 is often studied in combination therapies. It is also utilized in preclinical models to better understand ERK-dependent mechanisms in oncogenesis and drug resistance. Its application remains confined to experimental oncology and is not approved for clinical use.